Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 12/20 | 0.67 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22535735 | 0.88 | NTRK1 (0.72) | NTRK1IGF1R | |
| SCHEMBL22535599 | 0.85 | NTRK1 (0.66) | NTRK1IGF1R | |
| SCHEMBL22535827 | 0.84 | NTRK1 (0.67) | NTRK1 | |
| SCHEMBL22535630 | 0.83 | NTRK1 (0.66) | NTRK1 | |
| SCHEMBL4891282 | 0.83 | NTRK1 (0.88) | NTRK1IGF1R | |
| SCHEMBL4640146 | 0.83 | NTRK1 (0.73) | NTRK1IGF1R | |
| Valeric Acid SCHEMBL27708660 | 0.83 | NTRK1 (0.64) | NTRK1NEK1IGF1R | |
| SCHEMBL22535401 | 0.83 | NTRK1 (0.65) | NTRK1 | |
| SCHEMBL27738466 | 0.82 | NTRK1 (0.71) | NTRK1IGF1R | |
| SCHEMBL4737845 | 0.82 | NTRK1 (0.71) | NTRK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194606-A1 | Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer | ASTRAZENECA (SE) | 2008-08-14 | — | — | US | claimed |
| EP-1888561-A1 | PYRAZOLYL-AMINO- SUBSTITUTED PYRIMIDINES AND THEIR USE IN THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2008-02-20 | — | — | EP | claimed |
| WO-2006117560-A1 | PYRAZOLYL-AMINO- SUBSTITUTED PYRIMIDINES AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2006-11-09 | — | — | WO | claimed |
| US-20140179664-A1 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors | CELLZOME LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
| US-20140179664-A1 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors | CELLZOME LIMITED (GB) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179664-A1 | Heterocyclyl Pyrimidine Analogues As JAK Inhibitors | JAK1, JAK3, JAK2 | NTRK1 4690/4885NEK1 1557/4885IGF1R 1826/4885 |
| US-20080194606-A1 | Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer | TYMS, TYMP, DPYD | NTRK1 4196/4885NEK1 479/4885IGF1R 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.